Patents by Inventor Moussa B. H. Youdim

Moussa B. H. Youdim has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200354791
    Abstract: Provided herein are methods for prognosing and treating a patient with Parkinson's disease (PD) or Parkinsonian symptoms. The prognosis and appropriate treatments can be determined by correlating the level of gene expression of SKP1a, UBE2K, ALDH1A1, PSMC4, HSPA8 and LAMB2 with a Parkinson's Disease rating scale, thereby prognosing slow or rapid progression of the symptoms or disease.
    Type: Application
    Filed: November 8, 2018
    Publication date: November 12, 2020
    Applicant: BIO SHAI LTD.
    Inventors: Jennifer YARDEN, Nir DOTAN, Danit MECHLOVICH, Jose Martin RABEY, Moussa B. H. YOUDIM
  • Patent number: 9938235
    Abstract: The invention generally relates to compounds of formula (I) with neural protective effect, and preparation and uses thereof. The compounds have multiple mechanisms or functions, for example, inhibition of monoamine oxidase and cholinesterase, scavenging of free radicals, and protection of cells such as nerve cells. The compounds can be used for manufacture of medicaments of cell protection, for prevention and/or treatment of monoamine oxidase, cholinesterase and free radicals related diseases, for example, neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and stroke, and free-radical related diseases such as heart disease, myocardial ischemia, diabetes and other cardiovascular and cerebrovascular diseases.
    Type: Grant
    Filed: March 2, 2015
    Date of Patent: April 10, 2018
    Inventors: Yuqiang Wang, Moussa B. H. Youdim, Yewei Sun, Zaizun Zhang, Gaoxiao Zhang, Pei Yu, Peng Yi, Ming Lang, Wei Liu
  • Publication number: 20170151192
    Abstract: Disclosed is a method of treating Parkinson's disease and/or depression, and motor symptoms, non motor symptoms and depression symptoms associated with Parkinson's disease in a subject in need thereof, the method including administering to said subject a pharmaceutical composition comprising rasagiline or a pharmaceutically acceptable salt thereof, wherein the administering is effected by intranasal administration, and wherein a daily dose of the rasagiline or pharmaceutically acceptable salt thereof in the pharmaceutical composition is sufficient to inhibit monoamine oxidase (MAO)-A and MAO-B in a brain but insufficient to inhibit systemic MAO-A and therefore does not potentiate sympathetic cardiovascular activity associated with tyramine rich food consuming.
    Type: Application
    Filed: February 10, 2017
    Publication date: June 1, 2017
    Inventors: Moussa B.H. YOUDIM, Orly WEINREB, Tamar AMIT
  • Publication number: 20160326099
    Abstract: The invention generally relates to compounds of formula (I) with neural protective effect, and preparation and uses thereof. The compounds have multiple mechanisms or functions, for example, inhibition of monoamine oxidase and cholinesterase, scavenging of free radicals, and protection of cells such as nerve cells. The compounds can be used for manufacture of medicaments of cell protection, for prevention and/or treatment of monoamine oxidase, cholinesterase and free radicals related diseases, for example, neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and stroke, and free-radical related diseases such as heart disease, myocardial ischemia, diabetes and other cardiovascular and cerebrovascular diseases.
    Type: Application
    Filed: March 20, 2015
    Publication date: November 10, 2016
    Applicant: GUANGZHOU MAGPIE PHARMACEUTICAL CO., LTD
    Inventors: Yuqiang WANG, Moussa B.H. YOUDIM, Yewei SUN, Zaizun ZHANG, Gaoxiao ZHANG, Pei YU, Peng YI, Ming LANG, Wei LIU
  • Publication number: 20160022572
    Abstract: Compositions, methods and devices for intranasal administration of Rasagiline or a pharmaceutically acceptable salt thereof are disclosed. The compositions, devices and methods are for treating depression, Parkinson's disease and/or motor and depression symptoms associated with Parkinson's disease, by intranasal administration of an amount of Rasagiline or a pharmaceutically acceptable salt thereof that is sufficient to inhibit depressive illness in the subject and/or is sufficient to inhibit MAO-A in the brain of a subject.
    Type: Application
    Filed: March 13, 2014
    Publication date: January 28, 2016
    Inventors: Moussa B.H. YOUDIM, Orly WEINREB, Tamar AMIT
  • Patent number: 9034303
    Abstract: 8-Hydroxy-quinoline derivatives and 8-ethers, 8-esters, 8-carbonates, 8-acyloxymethyl, 8-phosphates, (phosphoryloxy)methyl, and 8-carbamates derivatives thereof are described that exhibit iron chelation, neuroprotective, neurorestorative, apoptotic and/or selective MAO-AB inhibitory activities.
    Type: Grant
    Filed: August 12, 2011
    Date of Patent: May 19, 2015
    Inventors: Vincent R. Zurawski, Jr., David M. Stout, Theodore J. Nitz, Moussa B. H. Youdim, Orly Weinreb
  • Patent number: 8802675
    Abstract: Multifunctional compounds are provided, comprising two or more functional moieties selected from: (i) a moiety that imparts an iron chelator function; (ii) a moiety that imparts a neuroprotective function; (iii) a moiety that imparts combined antiapoptotic, neuroprotective and/or neurorestorative functions; (iv) a moiety that imparts brain MAO inhibition, preferably with little or no MAO inhibition in liver and small intestine; (v) a moiety that imparts cholinesterase inhibitory function; and (vi) a moiety that imparts an N-methyl-D-aspartic acid receptor (NMDAR) inhibition, and pharmaceutically acceptable salts and optical isomers thereof. The multifunctional compounds are useful in the treatment or prevention of diseases, disorders or conditions that can be prevented and/or treated by iron chelation therapy, and/or neuroprotection and/or neurorestoration, and/or apoptosis inhibition and/or MAO inhibition and/or cholinesterase inhibition and/or NMADR inhibition.
    Type: Grant
    Filed: January 31, 2010
    Date of Patent: August 12, 2014
    Assignees: Technion Research and Development Foundation Ltd, Yeda Research and Development Company Ltd.
    Inventors: Moussa B. H. Youdim, Mati Fridkin, Hailin Zheng
  • Publication number: 20140186280
    Abstract: 8-Hydroxy-quinoline derivatives and 8-ethers, 8-esters, 8-carbonates, 8-acyloxymethyl, 8-phosphates, (phosphoryloxy)methyl, and 8-carbamates derivatives thereof are described that exhibit iron chelation, neuroprotective, neurorestorative, apoptotic and/or selective MAO-AB inhibitory activities.
    Type: Application
    Filed: March 4, 2014
    Publication date: July 3, 2014
    Inventors: Vincent R. ZURAWSKI, JR., David M. STOUT, Theodore J. NITZ, Moussa B.H. YOUDIM, Orly WEINREB
  • Patent number: 8685955
    Abstract: Novel iron chelators exhibiting neuroprotective and good transport properties are useful in iron chelation therapy for treatment of a disease, disorder or condition associated with iron overload and oxidative stress, e.g., a neurodegenerative or cerebrovascular disease or disorder, a neoplastic disease, hemochromatosis, thalassemia, a cardiovascular disease, diabetes, an inflammatory disorder, anthracycline cardiotoxicity, a viral infection, a protozoal infection, a yeast infection, retarding aging, and prevention and/or treatment of skin aging and skin protection against sunlight and/or UV light. The iron chelator function is provided by a 8-hydroxyquinoline, a hydroxypyridinone or a hydroxamate moiety. The neuroprotective function is imparted to the compound, e.g., by a neuroprotective peptide. A combined antiapoptotic and neuroprotective function is provided by a propargyl group.
    Type: Grant
    Filed: November 14, 2011
    Date of Patent: April 1, 2014
    Assignees: Technion Research and Development Foundation Ltd., Yeda Research and Development Co. Ltd.
    Inventors: Moussa B. H. Youdim, Matitiyahu Fridkin, Hailin Zheng, Rivka Warshawsky
  • Publication number: 20140045809
    Abstract: Transition metal complexes of amphiphilic corroles, optical isomers and pharmaceutically acceptable salts thereof are useful for neuroprotection and neurorescue, particularly for treatment of diabetes and neurodegenerative diseases. The amphiphilic corrole is preferably a 5,10,15-tris-aryl- or 5,10,15-tris-CF3-corrole, and said transition metal complex more preferably has the formula I defined in the specification. Also provided are propargyl-containing corroles carrying one or more radicals substituted by a propargylamino group or one or more nitrogen-containing heteroaryl radicals substituted by propargyl at the ring N atom.
    Type: Application
    Filed: September 3, 2013
    Publication date: February 13, 2014
    Applicant: TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD.
    Inventors: Moussa B.H. YOUDIM, Silvia MANDEL, Tamar AMIT, Orit BAR-AM, Lana KUPERSHMIDT, Zeev GROSS, Atif MAHAMMED, Irena SALTSMAN, Zoya OKUN
  • Publication number: 20130330284
    Abstract: 8-Hydroxy-quinoline derivatives and 8-ethers, 8-esters, 8-carbonates, 8-acyloxymethyl, 8-phosphates, (phosphoryloxy)methyl, and 8-carbamates derivatives thereof are described that exhibit iron chelation, neuroprotective, neurorestorative, apoptotic and/or selective MAO-AB inhibitory activities.
    Type: Application
    Filed: August 12, 2011
    Publication date: December 12, 2013
    Applicant: VARINEL INC
    Inventors: Vincent R. Zurawski, David M. Stout, Theodore J. Nitz, Moussa B.H. Youdim, Orly Weinreb
  • Publication number: 20130217028
    Abstract: The present invention relates to the use of molecular risk marker profiles for diagnosis of Parkinson's disease. More particularly, the invention provides methods for diagnosis of Parkinson's disease in an individual, utilizing certain profiles established based on the expression levels of certain genes, which together form a gene panel, in the peripheral blood of said individual, as well as kits for carrying out these methods. The profile encompass ALDH1A1.
    Type: Application
    Filed: October 26, 2011
    Publication date: August 22, 2013
    Inventors: Silva A. Mandel, Moussa B.H. Youdim, Peter Riederer, Edna Grunblatt, Jose M. Rabey, Leonid Molochnikov
  • Patent number: 8263655
    Abstract: Propargylamine, propargylamine derivatives N-propargyl-1-aminoindan and analogs thereof, and pharmaceutically acceptable salts thereof, are useful for administration to a subject at high risk for or suffering from acute renal failure (ARF).
    Type: Grant
    Filed: October 6, 2005
    Date of Patent: September 11, 2012
    Assignees: Technion Research and Development Foundation Ltd, Rappaport Family Institute
    Inventors: Ofer Binah, Zaid A. Abassi, Moussa B. H. Youdim, Yaron Barac
  • Publication number: 20120095107
    Abstract: Propargylamine, propargylamine derivatives including N-propargyl-l-aminoindan, enantiomers and analogs thereof, and pharmaceutically acceptable salts thereof, are useful for prevention or treatment of cardiovascular disorders, diseases and conditions.
    Type: Application
    Filed: December 23, 2011
    Publication date: April 19, 2012
    Applicants: RAPPAPORT FAMILY INSTITUTE FOR RESEARCH IN THE MEDICAL SCIENCES, TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD.
    Inventors: Moussa B.H. YOUDIM, Ofer Binah, Zaid A. Abassi, Yaron Barac
  • Publication number: 20120040993
    Abstract: Multifunctional compounds are provided, comprising two or more functional moieties selected from: (i) a moiety that imparts an iron chelator function; (ii) a moiety that imparts a neuroprotective function; (iii) a moiety that imparts combined antiapoptotic, neuroprotective and/or neurorestorative functions; (iv) a moiety that imparts brain MAO inhibition, preferably with little or no MAO inhibition in liver and small intestine; (v) a moiety that imparts cholinesterase inhibitory function; and (vi) a moiety that imparts an N-methyl-D-aspartic acid receptor (NMDAR) inhibition, and pharmaceutically acceptable salts and optical isomers thereof. The multifunctional compounds are useful in the treatment or prevention of diseases, disorders or conditions that can be prevented and/or treated by iron chelation therapy, and/or neuroprotection and/or neurorestoration, and/or apoptosis inhibition and/or MAO inhibition and/or cholinesterase inhibition and/or NMADR inhibition.
    Type: Application
    Filed: January 31, 2010
    Publication date: February 16, 2012
    Applicants: TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD., YEDA RESEARCH AND DEVELOPMENT CO., LTD.
    Inventors: Moussa B. H. Youdim, Mati Fridkin, Hailin Zheng
  • Patent number: 8097608
    Abstract: Propargylamine, propargylamine derivatives including N-propargyl-1-aminoindan, enantiomers and analogs thereof, and pharmaceutically acceptable salts thereof, are useful for prevention or treatment of cardiovascular disorders, diseases and conditions.
    Type: Grant
    Filed: June 9, 2006
    Date of Patent: January 17, 2012
    Assignees: Technion Research and Development Foundation Ltd., Rappaport Family Institute
    Inventors: Moussa B. H. Youdim, Ofer Binah, Zaid A. Abassi, Yaron Barac
  • Patent number: 8008284
    Abstract: Propargylamine, propargylamine derivatives including N-propargyl-1-aminoindan, enantiomers and analogs thereof, and pharmaceutically acceptable salts thereof, are useful for prevention or treatment of cardiovascular disorders, diseases and conditions.
    Type: Grant
    Filed: June 9, 2006
    Date of Patent: August 30, 2011
    Assignee: Technion Research and Development Foundation Ltd.
    Inventors: Moussa B. H. Youdim, Ofer Binah, Zaid A. Abassi, Yaron Barac
  • Publication number: 20100221735
    Abstract: The present invention relates to molecular markers for detection, prognosis and follow up of Parkinson's disease (PD), wherein said molecular markers are one or more genes with altered expression pattern, or gene products thereof (RNA or protein). Genes which expression is upregulated or downregulated in PD patients are tools for early diagnosis od PD, for monitoring the progress of the disease and can serve as targets for screening new agents for treatment of PD.
    Type: Application
    Filed: March 3, 2010
    Publication date: September 2, 2010
    Applicant: Technion Research & Development Foundation Ltd.
    Inventors: Moussa B.H. YOUDIM, Silvia A. Mandel, Edna Gr├╝nblatt, Peter Riederer
  • Publication number: 20090269770
    Abstract: The present invention provides methods for evaluating the pharmacological efficacy of drugs or drug candidates in treatment of psychiatric diseases or disorders, particularly schizophrenia, and for predicting the efficacy of drugs or drug combinations indicated for treatment of both positive and negative symptoms of psychiatric diseases or disorders in an individual having such a disease or disorder. In both methods, the drugs or drug candidates evaluated are assessed for their ability to produce certain changes in the expression of specific genes in peripheral mononuclear cells in blood of psychiatric patients, which are similar to the changes obtained following treatments with reference drugs or drug combinations effective against both positive and negative symptoms of psychiatric diseases or disorders.
    Type: Application
    Filed: April 24, 2009
    Publication date: October 29, 2009
    Applicant: Technion Research and Development Foundation Ltd.
    Inventors: Henry Silver, Moussa B.H. Youdim, Orly Weinreb
  • Publication number: 20090208979
    Abstract: The present invention provides a method for identifying a compound or a combination of compounds having a pharmacological behavior that qualifies it as a candidate for clinical development of a drug for treatment of a psychiatric disease or disorder, preferably schizophrenia. According to this method, a candidate drug is assessed for its ability to produce a biochemical profile, in either or both in vitro and in vivo test systems, which is similar to a unique reference biochemical profile obtained following treatments with drugs or drug combinations effective against both positive and negative symptoms of psychiatric diseases or disorders.
    Type: Application
    Filed: February 17, 2009
    Publication date: August 20, 2009
    Applicant: Technion Research and Development Foundation Ltd.
    Inventors: Henry SILVER, Moussa B.H. YOUDIM, Orly WEINREB